CA-MFA
7.9.2022 14:01:51 CEST | Business Wire | Press release
MFA, the industry Alliance supporting private network adoption, today announced that it is launching a new resource center on its website for enterprises to gain access to tools that will aid their 3GPP-based private network deployments and to highlight private networks globally. Enterprises can access these tools to simplify their own private network deployments and to learn about available spectrum options in their region.
“The connectivity requirements of enterprises are becoming more complex, with thousands of devices on a network conducting business-critical applications,” said Mazen Chmaytelli, president, MFA. “MFA is a leading industry resource for enterprises looking to understand the benefits and opportunities of 3GPP-based private networks for their business. Our mission is to make it as easy as possible for enterprises to deploy their own private network in any spectrum, and we are providing the tools and resources to help them facilitate that and achieve their digitalization goals.”
As part of its new private networks resource center, MFA is launching a private network tracker in partnership with industry analyst firm, Mobile Experts. The tracker provides insight into the state of private networks across various industry verticals and enterprises as well as regions where private networks are gaining ground.
“As of the end of June 2022, Mobile Experts estimates that more than 2,800 private LTE and 5G networks have been cumulatively deployed,” said Kyung Mun, principal analyst, Mobile Experts. “We also forecast that the private cellular equipment market will grow 12-15% this year to $1.9B and continue to ramp as the industrial device ecosystem scales. We also see that additional regulators are taking their cue from early actions in Germany, Japan, USA and the UK to make available dedicated private 5G spectrum. MFA will be providing ongoing updates on private network deployments globally so enterprises can learn about trends and best practices.”
New monthly newsletter
Enterprises are encouraged to subscribe to MFA’s new newsletter that will feature a monthly update on private networks deployed globally in a variety of industries, as well as feature new white papers, case studies, and resources. Subscribe at www.mfa-tech.org/newsletter.
Uni5G Technology Blueprints available for enterprises
MFA has also made its Uni5G™ Technology Blueprints publicly available for any enterprise to download. The blueprints leverage 3GPP 5G standards to define profiling and classification requirements for private networks. Enterprises can use the blueprints as a tool with their vendor of choice to let them know which select features their devices need to implement. The initial set of blueprints is based on 3GPP Release 15, and the next set of blueprints based on Release 16 and beyond are under development.
Meet us at Hannover Messe USA
MFA will be presenting at Hannover Messe USA in the Solutions Theater located in Building 1, Level 3.
- Monday, Sept. 12, 10:30-11:00AM: Practical Tools to Simplify Your Private Network Deployment by Mazen Chmaytelli, MFA President
- Friday, Sept. 16, 11:15-11:45AM: Deploying a Private 5G Network Doesn’t have to be Rocket Science by Asimakis Kokkos, MFA Technical Specification Group Chair
MFA representatives will also showcase technology solutions and resources in Booth #134661. To schedule a meeting with MFA’s private network experts, contact press@mfa-tech.org.
Resources:
- Download Uni5G Technology Blueprints
- White paper: The MFA Shared PLMN-ID – The ideal solution for your private network development
- View the global spectrum map
- Private network deployment tracker
- Subscribe to our newsletter, MFA Insights: Private Networks Report
About MFA
MFA is an industry Alliance supporting private network adoption. We provide resources that simplify the path to optimized, reliable and secure private networks in locally licensed, shared, or unlicensed spectrum. MFA enables the ecosystem with its free Uni5G™ Technology Blueprints and its unique global PLMN-ID program. Uni5G, based on 3GPP specifications, identifies the key 5G features needed for enterprises to successfully deploy their own private network. MFA is a 3GPP Market Representation Partner. Learn more at www.mfa-tech.org.
Become an MFA member
Join MFA as a contributor or an adopter member to participate in working groups, receive complimentary access to MFA’s Private Network Identifier packages, and to augment your company’s marketing activities. Learn more at Join | MFA (mfa-tech.org).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005526/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release
Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press release
We think Gartner recognizes Tecnotree's open, governed approach to agentic AI as operators make AI the engine of their revenue operations Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magi
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press release
Data Presented at Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS), Along with 6 Perceval Plus E-PostersEACTS Also Marks Commercial Launch of TriMemo and Memo 4D Curve, Innovative Repair Devices for Tricuspid and Mitral Valves Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
